Published in Am J Clin Dermatol on October 01, 2011
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Counterpoint: A tale of two meta-analyses revisited. J Am Acad Dermatol (2014) 0.76
Anti-TNFα therapy in the management of psoriasis: experience of a state referral center. An Bras Dermatol (2014) 0.75
Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease. Int Med Case Rep J (2016) 0.75
FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities. J Clin Aesthet Dermatol (2015) 0.75
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 6.23
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol (2009) 2.96
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med (2014) 2.36
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol (2011) 2.29
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol (2011) 2.13
Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis (2006) 1.94
Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci (2002) 1.75
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Current and potential uses of imiquimod. South Med J (2005) 1.70
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
Case reports of PML in patients treated for psoriasis. N Engl J Med (2013) 1.45
Community differentiation of the cutaneous microbiota in psoriasis. Microbiome (2013) 1.44
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Henoch-Schönlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol (2010) 1.39
Methotrexate and psoriasis: consensus conference. J Am Acad Dermatol (2011) 1.39
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2012) 1.33
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol (2008) 1.32
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol (2002) 1.29
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A (2004) 1.28
Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol (2010) 1.27
Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol (2009) 1.26
Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology (2014) 1.25
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2005) 1.18
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis (2009) 1.11
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis (2005) 1.09
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol (2010) 1.08
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol (2011) 1.06
Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology (2011) 1.05
A rare case of disseminated shingles in an immunocompetent patient following a 7-day treatment with oral valacyclovir. J Clin Virol (2008) 1.05
IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene (2004) 1.05
Genotypic analysis at multiple loci across Kaposi's sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. J Clin Virol (2002) 1.05
Acquired epidermodysplasia verruciformis. J Am Acad Dermatol (2009) 1.03
Ustekinumab. Nat Rev Drug Discov (2009) 1.02
Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol (2003) 1.01
Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. J Dtsch Dermatol Ges (2013) 1.00
Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol (2004) 1.00
One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis (2008) 0.98
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med (2015) 0.98
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. J Immunol (2011) 0.96
Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study. Int J Gynecol Pathol (2011) 0.96
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther (2005) 0.96
TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/- mice. J Immunol (2010) 0.95
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol (2011) 0.95
Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol (2005) 0.95
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol (2010) 0.94
Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-alpha and IL-4 and downregulated by IFN-gamma. Cytokine (2003) 0.94
Laser treatment of 26 Japanese patients with Mongolian spots. Dermatol Surg (2008) 0.94
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol (2011) 0.93
Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum (2003) 0.93
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol (2011) 0.92
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol (2012) 0.91
Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis (2008) 0.91
Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab (2005) 0.91
Scalp psoriasis. J Dtsch Dermatol Ges (2011) 0.91
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol (2011) 0.91
Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics (2003) 0.90
Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges (2007) 0.90
Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol (2008) 0.90
Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol (2005) 0.90
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol (2006) 0.90
Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers (2010) 0.90
Actinic granuloma. Dermatol Online J (2007) 0.90
Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol (2013) 0.90
A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg (2009) 0.89
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg (2014) 0.89
Cutaneous phaeohyphomycosis caused by Paraconiothyrium cyclothyrioides. J Clin Microbiol (2012) 0.89
German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges (2014) 0.89
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol (2010) 0.88
The direct action of 1alpha,25(OH)2-vitamin D3 on purified mouse Langerhans cells. Cell Immunol (2007) 0.88
Lichen planus pigmentosus-inversus occurring extensively in multiple intertriginous areas. J Dermatol (2011) 0.88
Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion (2003) 0.88
Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med (2004) 0.88
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol (2002) 0.88
Rational for statin use in psoriatic patients. Arch Dermatol Res (2013) 0.88
Is human immunodeficiency virus RNA load composed of neutralized immune complexes? J Infect Dis (2002) 0.87
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Arch Dermatol Res (2013) 0.87
Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res (2006) 0.87
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol (2010) 0.87